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Introduction
Breast cancer is the most common cancer diagnosed
in women in North America and 25 % of them are pre-
menopausal (1). The young pre-menopausal and peri-
menopausal women constitute a significant group of
patients with breast cancer and their specific treatment
requires careful consideration. Approximately 60% of
tumors in pre-menopausal women are hormone sensitive,
and are potentially suitable for endocrine treatment (2,3).
Systemic therapy which includes endocrine therapy and
chemotherapy are used to reduce the likelihood of
recurrence in early breast cancer (EBC) and to treat more
advanced disease with or without distant metastases.
Such therapy in the adjuvant setting in EBC will on
average reduce the risk of recurrence by 20-35% and the
odds of death by 15-30%. The adjuvant therapy decisions
are guided by numerous factors like tumor size, lymph
node status, hormone receptor status, HER2-neu over
expression, grade of the tumor, DNA synthesis rate, gene
profiling assay and host related factors like physiological
age of the patient, menopausal status and presence of co
morbid conditions.
Endocrine therapy: The presence of endogenous
estradiol plays a significant role in the progression of
disease and its impact is dependant on the hormone
receptor status of the tumor. Thus, removal of the some
of endogenous estrogen in pre-menopausal patients is
likely to prevent growth of tumors that are sensitive to
circulating estrogens. Hormonal manipulation has been
used for more than 100 years to treat young women with
advanced cancer, but there is still no complete consensus
about how to translate this into the management of EBC.
Tamoxifen, a selective estrogen receptor modulator
(SERM), is an effective agent for pre-menopausal women
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with hormone receptor positive status and 5 years of
tamoxifen is recognized as standard of care for these
women based on individual trials and Early Breast Cancer
Trialists Collaborative Group (EBCTCG) (4).
The definition of menopause in breast cancer patients
presents a tricky situation because of the confounding
factors like use of chemotherapy and hormonal therapy.
However, menopause is generally synonymous with
permanent cessation of menses and is accompanied by
profound and permanent decrease in estrogen synthesis
in ovaries. The universally accepted criteria for
determining menopause in the context of breast cancer
include any of those given in Table 1.
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HORIZONS
Table 1: Criteria for Defining Menopause in Breast Cancer patients
1. Prior bilateral oophorectomy
2. Age = 60 years
3. Age < 60 years and having amenorhoea for longer than 12 months
in the absence of chemotherapy or use of SERMs or OA/OS and
serum FSH and estradiol levels in the postmenopausal range
4. Serum FSH and estradiol levels in the postmenopausal range in a
patient with age < 60 years and taking SERMs
Oophorectomy in EBC: Ovarian ablation/suppression
(OA/OS) is acceptable adjuvant therapy in special
circumstances. In reviewing data from adjuvant trials
EBCTCG found that 2102 women under 50 years of age
with node-negative or node-positive EBC, ablation of
functioning ovaries by surgical oophorectomy or
radiotherapy significantly improved 15-year disease free
and overall survival compared with controls(5). This led
the National Institute of Health Consensus Conference
to endorse ovarian ablation or suppression as n alternative
to tamoxifen in 2000. Also the 2003 St. Gallen Consensus
Conference has suggested that OA/OS with tamoxifen
represents reasonable adjuvant therapy for some
intermediate risk premenopausal women. In direct andJK SCIENCE
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indirect comparisons, OA has been shown to have
comparable efficacy to chemotherapy, but OA by surgery
or RT induces permanent menopause with associated
long term effects such as loss f bone mineral density and
increased risk of cardiovascular problems (6).
Medical oophorectomy in EBC: Reversible ovarian
suppression can be induced by the use of luteinizing
hormone releasing hormone (LHRH) agonists alone or
with tamoxifen has proven effective for the treatment of
advanced breast cancer in pre-/perimenopausal women
resulting in objective response rates similar to
oophorectomy (7). LHRH agonists bind to the pituitary
receptors, resulting in receptor downregulation, which
leads to a profound suppression of LH and subsequently
estradiol. The benefit of this approach lies in its reliable
and reversible suppression of ovarian estrogen
production
Recently the results of five comparative trials of
adjuvant hormonal therapy using LHRH agonists alone
(8,9) or in combination with tamoxifen (10,11), versus
cytotoxic chemotherapy have shown at least equivalence
of effect in premenopausal women with hormone
receptor positive tumours. The Zoladex In
Premenopausal Patients (ZIPP) trial determined the effect
of adding goserelin to standard adjuvant treatment
(surgery ± radiotherapy ± chemotherapy ± tamoxifen)
compared with the effect of standard treatment alone in
women under the age of 50 years (12). After a median
follow up of 66 months, the event free survival was
significantly longer for patients who received goserelin
in addition to standard therapy compared with those who
did not (HR=0.80, p<0.001). Overall survival was also
significantly prolonged (HR=0.82, p=0.04). Another trial
addressed the question of value of the addition of
chemotherapy to goserelin therapy. The International
Breast Cancer Study Group (IBCSG) Trial VIII was
designed to compare six cycles of CMF with either 2
years goserelin, six cycles CMF followed by 18 months
goserelin or no treatment in premenopausal women with
node negative EBC. Interim analysis of 200 patients from
the four original arms showed significantly longer 5 year
DFS in the treated group (77% vs. 60%, p0.02) (13).
Subsequent analysis showed that 5-year DFS were
comparable in the three treatment arms (goserelin 81%;
CMF 81%; CMF plus goserelin 88%) and there is no
benefit of adding CMF chemotherapy to goserelin in
node-negative, estrogen receptor-positive premenopausal
breast cancer patients (14).
The Future of Medical Oophorectomy in EBC:
Despite these advances in the understanding of hormone
therapy in breast cancer, a number of questions still
remain unanswered viz. the value of combining or
sequencing OA with chemotherapy; the value of
combining OA with tamoxifen or aromatase inhibitors;
and the utility of chemotherapy in premenopausal women
with hormone responsive breast cancer who are already
receiving endocrine therapy. Three prominent
international trials are going on to address these issues.
The Suppression of Ovarian Function Trial (SOFT) is
randomizing premenopausal ER-positive or PR-positive
tumors to 5 years of tamoxifen alone, 5 years of
tamoxifen and GnRH agonist triptorelin, and 5 years of
the exemestane with triptorelin.   Tamoxifen and
Exemestane Trial (TEXT) compares ovarian ablation (5
years of triptorelin) and tamoxifen with 5 years of
triptorelin and exemestane. In the Premenopausal
Endocrine Responsive Chemotherapy Trial (PERCHE),
premenopausal women all receive OA with the triptorelin
and then are randomly assigned to receive chemotherapy
or no chemotherapy, followed by a subsequent random
assignment to receive tamoxifen or exemestane.
Current treatment guidelines from St. Gallen and the
European Society of Mastology (EUSOMA) now
recommend the use of a LHRH agonist for 2 years with
or without tamoxifen for 5 years, as an alternative to
adjuvant cytotoxic chemotherapy for premenopausal
women with hormone sensitive early breast cancer. Such
treatment is also recommended for those women treated
with chemotherapy whose menses return or who fail to
achieve castrate levels of estrogens or follicle stimulating
hormone after completing chemotherapy
Conclusion
The available data suggest that OA/OS provides a
valuable treatment option in premenopausal patients with
hormone receptor positive status and may be an attractive
alternative to cytotoxic chemotherapy without theJK SCIENCE
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associated distressing side effects. However, most of
these trials did not use  anthracyclines or taxanes, and
used tamoxifen inconsistently. OA/OS itself is associated
with adverse effects like weight gain, diabetes and hot
flashes. As of now, OA should not be routinely used to
replace adjuvant chemotherapy in premenopausal women
with breast cancer. But it does offer a means of avoiding
chemotherapy which may be a requirement in some
patients. And it can also be used as a treatment combined
with tamoxifen or aromatase inhibitors and/or
chemotherapy in some selected patients with beneficial
results.
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